What a week at ISPOR 2026!
The OMNY Health team had a highly productive and impactful showing at this year’s annual conference. We anchored our presence with one podium presentation and six poster presentations—including a standout client-led poster utilizing OMNY Health data.
Our featured research spanned a diverse array of therapeutic areas, economic evaluations, and advanced methodological frameworks, demonstrating our robust capabilities in health economics and outcomes research (HEOR). From mental health and metabolic outcomes to respiratory and immunology research, these studies highlight the critical role that high-quality real-world data (RWD) plays in modern evidence generation.
Beyond our own presentations, our team spent the week engaging with the definitive themes shaping the future of HEOR: the evolution of AI adoption and advanced evidence generation in oncology.
A major takeaway from the sessions on AI and Large Language Models (LLMs) is the critical shift from manual abstraction to automated, scalable data enrichment.
- The Challenge: The industry faces an unprecedented demand for RWD, but a massive volume of clinical narrative remains locked in unstructured electronic health records (EHRs) and physician notes. Traditional manual abstraction is costly, slow, and unsustainable.
- The Methodological Solution: Discussions highlighted advanced AI optimization frameworks—splitting AI into Machine Learning (ML) for predictive risk profiling and Natural Language Processing (NLP) for clinical text recognition. Leading methodologies are deploying multi-layered approaches (combining web scraping, PDF processing, and rule-based parsing with prompt-specific LLMs) alongside quality frameworks like the Kahn Framework to eliminate false negatives and capture missing variables (such as nuanced Social Determinants of Health).
- The OMNY Advantage: At OMNY Health, this is exactly where our AI services add distinct value. By converting unstructured text into structured, normalized data spaces , we bypass traditional site-visitation. We augment existing HEOR methods to deliver high-fidelity, generalizable datasets ready for advanced applications like digital twins and regulatory-grade evidence generation.
Oncology continues to be a frontier where conventional evidence paradigms fall short, especially as discussed in the cancer plenary on the financial toxicity of care and the rare cancer forums.
- The Challenge: Generating credible real-world evidence (RWE) in oncology—particularly rare cancers—is routinely restricted by small sample sizes, single-arm designs, and highly fragmented data across the care continuum. Furthermore, regulatory bodies and Health Technology Assessment bodies (HTAbs) demand strict adherence to data quality frameworks.
- The Methodological Solution: To accelerate market access and build stakeholder trust, the industry is moving toward advanced methods like target trial emulation, external control arms, and robust EHR-derived data quality frameworks to validate longitudinal patient journeys.
- The OMNY Advantage: Our specialized oncology data offering directly answers this call. OMNY’s large, US-based oncology EHR-derived database is built with rigorous regulatory data quality frameworks in mind. By integrating medicines, molecular testing, and medical services across the care continuum, we provide life sciences companies and researchers with the deep, longitudinally complete data required to evaluate complex variables, track treatment adherence, and demonstrate true patient-centered value.
A huge thank you to everyone who stopped by our sessions, visited our posters, or took the time to connect with our team! We loved catching up with familiar faces and sparking new collaborations.
The conversations we had reinforce how vital high-quality RWD and intelligent AI extraction are to shaping the future of healthcare. We’re looking forward to continuing these discussions, supporting regulatory buy-in, and driving the industry forward together.
Missed us at the event but want to learn more about our advanced oncology data capabilities or AI-driven RWD solutions? Let’s connect!